Reports

Drug name	NICE TAs	Comments
Asciminib	TA813: Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors
Asfotase alfa		NHSE commissioned
Asparaginase 10,000 units injection (5 vials)
Aspirin suppositories
Atezolizumab (Tecentriq®)	TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable TA823: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer
Atezolizumab (Tecentriq®)	TA492 - Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable TA520 - Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy TA525 - Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy TA333 - Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment TA584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer TA639 - Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer TA638 - Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma TA705 - Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer	Hospital use only
Atomoxetine		ESCAs and additional advice in relation to age of patient and CCG
Atosiban (Tractocile)
Atracurium injection
Atropine injection#15.1

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
Next page
Last page

University Hospitals Birmingham NHS Foundation Trust

Medicines Formulary

Reports